Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
Laboratory studies suggest that the study drug may stop cancer cells from growing by
affecting an interaction between proteins in the cells referred to as cAMP-response
element-binding protein and ß-catenin.
The purpose of this research study is to determine the highest safe dose of study drug that
may be used when it is given together with a chemotherapy drug to patients with cancer of the
pancreas.